Organization (Industry)
SciClone Pharmaceuticals (United States)
ClinicalTrials.gov lists SciClone Pharmaceuticals (United States) as lead sponsor of 16 trials. It has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers SciClone Pharmaceuticals (United States): 16 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (21)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hepatitis C | 5 |
| Hepatitis C, Chronic | 5 |
| Lung Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Head and Neck Neoplasms | 2 |
Showing 5 of 21 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2016 | 3 |
| 2015 | 1 |
| 2010 | 2 |
| 2009 | 1 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Naxitamab | 1 |
| PEGinterferon alfa-2a | 1 |
| GEMCITABINE | 1 |
| ELacestrant | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | not enough data |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of the New York Academy of Sciences | 2 |
| Expert opinion on biological therapy | 2 |
| The Cochrane database of systematic reviews | 2 |
| BMJ (Clinical research ed.) | 1 |
| BMJ open | 1 |
Showing 5 of 13 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 21 | 0 | 2017-08-08 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| FDA Office of Orphan Products Development | Co sponsors trial with | 1 |
Latest dated events (43)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-08-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-07-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 43 events.
Biomarker capability evidence (66)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 66 evidence rows.
On Scientist.com
SciClone Pharmaceuticals (United States) is listed as a research supplier in the Scientist.com network.
Service areas
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s proprietary lead product, ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical...
Show the full description
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.
SciClone’s proprietary lead product, ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company’s long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN.
- Website
- www.sciclone.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Sciclone on Scientist.com
For prices, more details, or to contact Sciclone, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.